Dr. Reddy's Laboratories will announce their Q2 numbers on Wednesday. On a year-on-year (YoY) basis the numbers will look weaker this time around because last year there was Rs 700 crore worth of licensing income and also a tax credit. Revenues are expected to be flat at Rs 4,800 crore, EBITDA is expected to decline by 21 percent.
Margins should see a contraction of almost 500 basis points and profits accordingly should see a decline of 41 percent.
Expect growth in US markets because on a quarter-on-quarter (QoQ) basis there have been certain launches and that is why 20 million dollar sequential improvement is what is expected in terms of US revenues.
Expect 18 percent YoY growth in India business because Wockhardt integration will be seen in the Indian market his time around.
Watch the full video for more details(Edited by : Vrushali Sawant)
First Published: Oct 27, 2020 4:58 PM IST